News >

Adjuvant Atezolizumab Misses DFS Endpoint in Muscle-Invasive Bladder Cancer

Gina Columbus @ginacolumbusonc
Published: Friday, Jan 24, 2020

Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development of Genentech (Roche)

Levi Garraway, MD, PhD

Adjuvant treatment with atezolizumab (Tecentriq) did not significantly improve disease-free survival (DFS) compared with observation in patients with muscle-invasive bladder cancer, missing the primary endpoint of the phase III IMvigor010 trial (NCT02450331).1

Atezolizumab is currently approved by the FDA for the frontline treatment of patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy and whose tumors express PD-L1, or those who are not eligible for any platinum-based chemotherapy, regardless of PD-L1 status. The PD-L1 inhibitor is also indicated for the treatment of patients with locally advanced or metastatic urothelial cancer whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving a platinum-containing chemotherapy, either before or after surgery.


  1. Genentech provides an update on phase III study of Tecentriq in people with muscle-invasive urothelial cancer [news release]: San Francisco, CA. Genentech. Published January 23, 2020. Accessed January 23, 2020.        
  2. Grande E, Galsky MD, Arranz Arija JA, et al. IMvigor130: a phase III study of atezolizumab with or without platinum-based chemotherapy in previously untreated metastatic urothelial carcinoma. Ann Oncol. 2019;30(suppl_5):v851-v934. doi: 10.1093/annonc/mdz394.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication